Long-term outcomes after surgical dissection of inguinal lymph node metastasis from rectal or anal canal adenocarcinoma.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
24 Jul 2019
Historique:
received: 30 09 2018
accepted: 18 07 2019
entrez: 26 7 2019
pubmed: 26 7 2019
medline: 15 2 2020
Statut: epublish

Résumé

The 8th edition of the tumor-node-metastasis (TNM) classification classifies inguinal lymph nodes as regional lymph nodes for anal canal carcinoma but non-regional lymph nodes for rectal carcinoma. This difference might reflect the different prognosis of inguinal lymph node metastasis from anal canal carcinoma and rectal carcinoma. However, long-term outcomes of inguinal lymph node metastasis from rectal or anal canal adenocarcinoma are unclear, which we aimed to investigate in this study. The study population included 31 consecutive patients with rectal or anal canal adenocarcinoma who underwent inguinal lymph node dissection with curative intent at the National Cancer Center Hospital from 1986 to 2017. Long-term outcomes were assessed and clinicopathologic variables analyzed for prognostic significance. Of the 31 patients, 12 patients had rectal adenocarcinoma and 19 patients had anal canal adenocarcinoma. Synchronous metastasis were observed in 14 patients and metachronous metastasis in 17 patients. After dissection of inguinal lymph node metastasis with curative intent, the 5-year overall survival rate was 55.2%, with 12 patients surviving for more than 5 years. Median survival time was 66.6 months. Multivariate analyses revealed that location of primary tumor (rectum versus anal canal) was not a prognostic factor, whereas lateral lymph node metastasis and histological findings were independent prognostic factors. Given the good prognosis, inguinal lymph node metastasis in patients with rectal or anal canal adenocarcinoma appears to be regional rather than distant. If R0 resection can be achieved, inguinal lymph node dissection may be indicated for these patients.

Sections du résumé

BACKGROUND BACKGROUND
The 8th edition of the tumor-node-metastasis (TNM) classification classifies inguinal lymph nodes as regional lymph nodes for anal canal carcinoma but non-regional lymph nodes for rectal carcinoma. This difference might reflect the different prognosis of inguinal lymph node metastasis from anal canal carcinoma and rectal carcinoma. However, long-term outcomes of inguinal lymph node metastasis from rectal or anal canal adenocarcinoma are unclear, which we aimed to investigate in this study.
METHODS METHODS
The study population included 31 consecutive patients with rectal or anal canal adenocarcinoma who underwent inguinal lymph node dissection with curative intent at the National Cancer Center Hospital from 1986 to 2017. Long-term outcomes were assessed and clinicopathologic variables analyzed for prognostic significance.
RESULTS RESULTS
Of the 31 patients, 12 patients had rectal adenocarcinoma and 19 patients had anal canal adenocarcinoma. Synchronous metastasis were observed in 14 patients and metachronous metastasis in 17 patients. After dissection of inguinal lymph node metastasis with curative intent, the 5-year overall survival rate was 55.2%, with 12 patients surviving for more than 5 years. Median survival time was 66.6 months. Multivariate analyses revealed that location of primary tumor (rectum versus anal canal) was not a prognostic factor, whereas lateral lymph node metastasis and histological findings were independent prognostic factors.
CONCLUSION CONCLUSIONS
Given the good prognosis, inguinal lymph node metastasis in patients with rectal or anal canal adenocarcinoma appears to be regional rather than distant. If R0 resection can be achieved, inguinal lymph node dissection may be indicated for these patients.

Identifiants

pubmed: 31340778
doi: 10.1186/s12885-019-5956-y
pii: 10.1186/s12885-019-5956-y
pmc: PMC6657054
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

733

Références

J Surg Oncol. 1999 Mar;70(3):177-80
pubmed: 10102348
Dis Colon Rectum. 1999 Nov;42(11):1464-6
pubmed: 10566535
Cancer. 2001 Jul 1;92(1):77-84
pubmed: 11443612
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
Ann Surg. 1942 Aug;116(2):200-16
pubmed: 17858082
Radiother Oncol. 2009 Jul;92(1):22-33
pubmed: 19095323
Colorectal Dis. 2010 Apr;12(4):312-5
pubmed: 19250258
Colorectal Dis. 2010 Oct;12(10 Online):e200-5
pubmed: 19912287
Br J Surg. 2010 Jul;97(7):1110-8
pubmed: 20632280
Dis Colon Rectum. 1990 Mar;33(3):212-6
pubmed: 2311465
Int J Colorectal Dis. 2013 Dec;28(12):1675-80
pubmed: 23836116
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):638-45
pubmed: 24035327
PLoS One. 2014 Nov 19;9(11):e111770
pubmed: 25409168
BMJ. 2016 Apr 27;352:i1981
pubmed: 27121591
Lancet Oncol. 2016 Dec;17(12):1709-1719
pubmed: 27743922
Int J Epidemiol. 2017 Jun 1;46(3):924-938
pubmed: 27789668
Liver Cancer. 2016 Nov;6(1):66-71
pubmed: 27995090
Int J Clin Oncol. 2018 Feb;23(1):1-34
pubmed: 28349281
J Cancer. 2017 Apr 9;8(6):1097-1102
pubmed: 28529624
Ann Surg Oncol. 2018 Jan;25(1):173-178
pubmed: 29063295
Ann Surg Oncol. 2018 Jun;25(6):1646-1653
pubmed: 29572704
J Natl Compr Canc Netw. 2018 Jul;16(7):852-871
pubmed: 30006428
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901
pubmed: 30006429
Jpn J Clin Oncol. 2019 Apr 1;49(4):321-328
pubmed: 30608547

Auteurs

Taro Tanabe (T)

Department of Colorectal Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.

Dai Shida (D)

Department of Colorectal Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan. dshida@ncc.go.jp.

Sho Komukai (S)

Division of Biomedical Statistics, Department of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.

Yuya Nakamura (Y)

Department of Colorectal Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.

Shunsuke Tsukamoto (S)

Department of Colorectal Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.

Yukihide Kanemitsu (Y)

Department of Colorectal Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH